Alphatec Holdings, Inc. (ATEC) rated Outperform with price target $7 by Boenning & Scattergood
Alphatec Holdings, Inc. (NASDAQ: ATEC)
rated Outperform with price target $7 by Boenning & Scattergood.
Alphatec Holdings, Inc.
, is a medical technology company focused on the design, development, manufacturing and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio and pipeline includes a variety of spinal disorder products and systems focused on solutions addressing the cervical, thoracolumbar, intervertebral, minimally invasive, motion preservation, vertebral compression fracture, and osteoporotic bone markets. Products and systems are made of titanium, titanium alloy, stainless steel and polyetheretherketone (PEEK). The Company also sells products made of allograft, a precision-milled and processed human bone that surgeons can use in place of metal and synthetic materials. Bone-grafting products that are comprised of both tissue-based and synthetic materials are also available.
Our equity research team concentrates on companies that aren’t widely covered in sectors such as water distribution/equipment/technology, financial services, business services, aerospace & defense technology, medical technology and retail.